US Patent

US10617693 — Methods of treating and/or preventing actinic keratosis

Method of Use · Assigned to Athenex Inc · Expires 2038-03-12 · 12y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods of treating and/or preventing actinic keratosis by administering a therapeutically effective amount of KX-01 to a subject.

USPTO Abstract

The application pertains to methods of treating and/or preventing actinic keratosis, comprising administering a therapeutically effective amount of KX-01, to a subject in need thereof.

Drugs covered by this patent

Klisyri (TIRBANIBULIN) · Almirall

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3015`	—	Klisyri

Patent Metadata

Patent number: US10617693
Jurisdiction: US
Classification: Method of Use
Expires: 2038-03-12
Drug substance claim: No
Drug product claim: No
Assignee: Athenex Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.